JP2019504631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504631A5 JP2019504631A5 JP2018541222A JP2018541222A JP2019504631A5 JP 2019504631 A5 JP2019504631 A5 JP 2019504631A5 JP 2018541222 A JP2018541222 A JP 2018541222A JP 2018541222 A JP2018541222 A JP 2018541222A JP 2019504631 A5 JP2019504631 A5 JP 2019504631A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- genetically modified
- immunocompetent
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004027 cell Anatomy 0.000 claims 31
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 210000000822 natural killer cell Anatomy 0.000 claims 9
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 claims 8
- 101000858031 Homo sapiens Coxsackievirus and adenovirus receptor Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 241000701161 unidentified adenovirus Species 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 102000009490 IgG Receptors Human genes 0.000 claims 3
- 108010073807 IgG Receptors Proteins 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 230000000139 costimulatory effect Effects 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000002352 blister Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291999P | 2016-02-05 | 2016-02-05 | |
| US62/291,999 | 2016-02-05 | ||
| PCT/US2017/016543 WO2017136748A1 (en) | 2016-02-05 | 2017-02-03 | Compositions and methods for recombinant cxadr expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504631A JP2019504631A (ja) | 2019-02-21 |
| JP2019504631A5 true JP2019504631A5 (enExample) | 2020-03-12 |
Family
ID=59500016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541222A Abandoned JP2019504631A (ja) | 2016-02-05 | 2017-02-03 | 組換えｃｘａｄｒ発現のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190046570A1 (enExample) |
| EP (1) | EP3411474A4 (enExample) |
| JP (1) | JP2019504631A (enExample) |
| KR (1) | KR20180102108A (enExample) |
| CN (1) | CN108884443A (enExample) |
| AU (1) | AU2017214581A1 (enExample) |
| CA (1) | CA3012472A1 (enExample) |
| WO (1) | WO2017136748A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111727262A (zh) * | 2017-07-25 | 2020-09-29 | 加州理工学院 | 胞啃介导的表位发现 |
| CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| CN119876018B (zh) * | 2024-12-16 | 2026-01-30 | 广东志珞生物科技有限公司 | 一种nk细胞及其在制备抗肿瘤药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994132A (en) * | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| US20020016974A1 (en) * | 2000-02-16 | 2002-02-07 | Woodland Robert T. | Transgenic, non-human animals containing a coxsackie/adenovirus receptor (CAR) |
| CN100471957C (zh) * | 2002-04-30 | 2009-03-25 | 艾维亚医药/生物技术有限公司 | 用于免疫治疗的腺病毒载体 |
| ES2806776T3 (es) * | 2014-06-18 | 2021-02-18 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Células NK-92 que expresan CAR como agentes terapéuticos celulares |
-
2017
- 2017-02-03 CA CA3012472A patent/CA3012472A1/en not_active Abandoned
- 2017-02-03 JP JP2018541222A patent/JP2019504631A/ja not_active Abandoned
- 2017-02-03 EP EP17748289.0A patent/EP3411474A4/en not_active Withdrawn
- 2017-02-03 KR KR1020187022005A patent/KR20180102108A/ko not_active Withdrawn
- 2017-02-03 CN CN201780009615.2A patent/CN108884443A/zh not_active Withdrawn
- 2017-02-03 AU AU2017214581A patent/AU2017214581A1/en not_active Abandoned
- 2017-02-03 US US16/073,947 patent/US20190046570A1/en not_active Abandoned
- 2017-02-03 WO PCT/US2017/016543 patent/WO2017136748A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tian et al. | Engineering strategies to enhance oncolytic viruses in cancer immunotherapy | |
| Heidbuechel et al. | Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies | |
| Zhang et al. | Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic | |
| CN109862912B (zh) | 携带双特异性t细胞衔接器的腺病毒 | |
| Jones et al. | Cell surface–tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy | |
| Yu et al. | T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy | |
| Ye et al. | An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ | |
| JP6754532B2 (ja) | 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用 | |
| Qiu et al. | Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8+ T-cell response and protects mice from melanoma | |
| Ylösmäki et al. | Personalized cancer vaccine platform for clinically relevant oncolytic enveloped viruses | |
| Vasconcelos et al. | Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine | |
| JP2010527919A5 (enExample) | ||
| WO2022098905A2 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| Erkes et al. | Intratumoral infection with murine cytomegalovirus synergizes with PD-L1 blockade to clear melanoma lesions and induce long-term immunity | |
| CN115243700A (zh) | 治疗性细胞组合物及其制造方法和用途 | |
| US20200270574A1 (en) | CD1d and TCR-NKT Cells | |
| JP2024510712A (ja) | Ｉｌ－１５をコードするアデノウイルス | |
| JP2019504631A5 (enExample) | ||
| CA3073310A1 (en) | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody | |
| US20230190922A1 (en) | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer | |
| US20220195006A1 (en) | Peptide markers to track genetically engineered cells | |
| JP2020524145A5 (enExample) | ||
| JP2022512595A (ja) | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 | |
| Liu et al. | Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models | |
| Ni et al. | Antitumor vaccination by Newcastle Disease Virus Hemagglutinin–Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity |